Virtus Advisers LLC Invests $58,000 in SiBone $SIBN

Virtus Advisers LLC bought a new position in SiBone (NASDAQ:SIBN) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,132 shares of the company’s stock, valued at approximately $58,000.

A number of other hedge funds have also modified their holdings of SIBN. Johnson Investment Counsel Inc. acquired a new stake in SiBone during the 1st quarter valued at $148,000. Rhumbline Advisers increased its holdings in SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock valued at $838,000 after purchasing an additional 2,100 shares in the last quarter. GAMMA Investing LLC increased its holdings in SiBone by 20,352.6% during the 1st quarter. GAMMA Investing LLC now owns 3,886 shares of the company’s stock valued at $55,000 after purchasing an additional 3,867 shares in the last quarter. MetLife Investment Management LLC increased its holdings in SiBone by 17.6% during the 4th quarter. MetLife Investment Management LLC now owns 27,421 shares of the company’s stock valued at $384,000 after purchasing an additional 4,104 shares in the last quarter. Finally, Deutsche Bank AG increased its holdings in SiBone by 53.0% during the 4th quarter. Deutsche Bank AG now owns 36,268 shares of the company’s stock valued at $508,000 after purchasing an additional 12,561 shares in the last quarter. 98.11% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director John Gordon Freund sold 12,132 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $15.99, for a total value of $193,990.68. Following the transaction, the director directly owned 91,767 shares in the company, valued at $1,467,354.33. This trade represents a 11.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Laura Francis sold 11,343 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $15.60, for a total value of $176,950.80. Following the completion of the transaction, the chief executive officer owned 419,704 shares in the company, valued at $6,547,382.40. This represents a 2.63% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 49,967 shares of company stock worth $829,469 over the last three months. Insiders own 3.90% of the company’s stock.

SiBone Stock Down 2.1%

Shares of SIBN opened at $16.05 on Tuesday. The firm has a market capitalization of $692.40 million, a price-to-earnings ratio of -28.66 and a beta of 0.91. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38. The business’s fifty day moving average price is $17.03 and its two-hundred day moving average price is $16.51. SiBone has a 52 week low of $11.70 and a 52 week high of $20.05.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. The firm had revenue of $48.63 million for the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. SiBone has set its FY 2025 guidance at EPS. On average, analysts predict that SiBone will post -0.78 earnings per share for the current year.

Analyst Ratings Changes

SIBN has been the subject of a number of recent analyst reports. Wall Street Zen cut SiBone from a “buy” rating to a “hold” rating in a report on Saturday, August 9th. Needham & Company LLC reaffirmed a “buy” rating and set a $24.00 price target on shares of SiBone in a report on Tuesday, May 6th. Truist Financial raised their price target on SiBone from $20.00 to $22.00 and gave the company a “buy” rating in a report on Tuesday, May 6th. Finally, Cantor Fitzgerald set a $25.00 price target on SiBone and gave the company an “overweight” rating in a report on Monday, August 11th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the company has an average rating of “Buy” and an average price target of $23.67.

About SiBone

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.